Mario Balsa/X
Jul 13, 2025, 13:57
Mario Balsa: A PI3K Path Worth Walking – If You Can Manage the Steps
Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology (ICO), shared a post on X:
“INAVO120 (NEJM): In PIK3CA-mutated, HR+/HER2– endocrine-resistant MBC, inavolisib + palbociclib + fulvestrant vs placebo:
- mOS: 34.0 vs 27.0 mo (HR 0.67; p=0.02)
- Higher AEs: 6.8% d/c due to toxicity
A PI3K path worth walking – if you can manage the steps.
Congrats to Komal Jhaveri and all the team!”
Title: Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer
Journal: NEJM
Authors: Komal L. Jhaveri, Seock-Ah Im, Cristina Saura, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Eirini Thanopoulou, Noopur Shankar, Yanling Jin, Thomas J. Stout, Tiffany D. Clark, Chunyan Song, Dejan Juric, Nicholas C. Turner
More posts featuring Mario Balsa on OncoDaily.
cancer
Catalan Institute of Oncology
Chunyan Song
Cristina Saura
Dejan Juric
Eirini Thanopoulou
Fulvestrant
ICO
INAVO120
Inavolisib
Kevin Kalinsky
Komal Jhaveri
Komal L. Jhaveri
Mario Balsa
Nicholas C. Turner
Noopur Shankar
OncoDaily
Oncology
palbociclib
Peter Schmid
PIK3CA-mutated breast cancer
Seock-Ah Im
Sherene Loi
Sibylle Loibl
Thomas J Stout
Tiffany D. Clark
Yanling Jin
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 13, 2025, 13:57
Jul 13, 2025, 13:54
Jul 13, 2025, 13:50
Jul 13, 2025, 13:47
Jul 13, 2025, 13:40
Jul 13, 2025, 13:34
Jul 13, 2025, 13:25
Jul 13, 2025, 13:20